Drug intelligence / Profile preview

PCSK9 inhibitors + bempedoic acid + ezetimibe

Development stage: Unknown
Lead developer: Esperion Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Subcutaneous

Overview

A triple combination lipid-lowering therapy that works through complementary mechanisms to significantly reduce LDL cholesterol levels. PCSK9 inhibitors increase LDL receptor availability, bempedoic acid inhibits hepatic cholesterol synthesis via ATP citrate lyase inhibition, and ezetimibe blocks intestinal cholesterol absorption. This combination is particularly valuable for patients with statin intolerance or those who cannot achieve target LDL-C levels with standard therapy.

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)ACLY (ATP-citrate synthase)

Beyond the preview

Go deeper on PCSK9 inhibitors + bempedoic acid + ezetimibe.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCSK9 inhibitors + bempedoic acid + ezetimibe.

Explore the full profile